Primary Intra-Arterial Chemotherapy for Retinoblastoma in the Intravitreal Chemotherapy Era: Five Years of Experience.
Publication/Presentation Date
2-1-2019
Abstract
PURPOSE: To report our 5-year experience with intra-arterial chemotherapy (IAC) in the intravitreal chemotherapy (IvitC) era.
METHODS: Retrospective review of retinoblastoma treated with primary unilateral IAC in the IvitC era (2012-2017).
RESULTS: There were 34 eyes treated with IAC alone versus 20 eyes treated with IAC plus IvitC for vitreous seeds. IAC (IAC alone vs. IAC plus IvitC) consisted of melphalan (41 vs. 10%) or melphalan plus topotecan (59 vs. 90%,
CONCLUSIONS: IAC is effective as primary therapy for unilateral group B, C, D, and E retinoblastoma. IvitC is an important adjuvant therapy to achieve comparable globe salvage rates for group D and E eyes with persistent active vitreous seeds.
Volume
5
Issue
2
First Page
139
Last Page
146
ISSN
2296-4681
Published In/Presented At
Dalvin, L. A., Kumari, M., Essuman, V. A., Shohelly Shipa, S., Ancona-Lezama, D., Lucio-Alvarez, J. A., Jabbour, P., & Shields, C. L. (2019). Primary Intra-Arterial Chemotherapy for Retinoblastoma in the Intravitreal Chemotherapy Era: Five Years of Experience. Ocular oncology and pathology, 5(2), 139–146. https://doi.org/10.1159/000491580
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
30976594
Department(s)
Administration and Leadership
Document Type
Article